How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

848 results for

Rivastigmine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

163. Recommendations on screening for cognitive impairment in older adults

important change. The MMSE and the MoCA tools are commonly used by Canadian clinicians in clinical practice. 14 Treatments include medications such as cho- linesterase inhibitors (i.e., donepezil, rivastigmine and galantamine), dietary supplements and vita- mins, and nonpharmacologic interventions such as exercise, and cognitive training and rehabili- tation. 10 Provincial payment for the medications used in primary care practice is often linked to cognitive assessment scores measured by the screening (...) interventions approved for use in Canada (e.g., cholinesterase inhibitors, such as donepezil, rivastigmine and galantamine), dietary supplements or vitamins and nonpharmacologic interventions (e.g., exer- cise, cognitive training and rehabilitation). The task force workgroup decided to treat the key question regarding the accuracy of screening tools (key question 6 in Appendix 2) as a contex- tual question. This was because there were no trials of screening programs and there was evi- dence that treatment

2015 CPG Infobase

164. Pharmacological interventions for unilateral spatial neglect after stroke. Full Text available with Trip Pro

low-quality evidence from one trial (20 participants) comparing effects of rivastigmine plus rehabilitation versus rehabilitation on overall USN at discharge showed the following: Barrage (mean difference (MD) 0.30, 95% confidence interval (CI) -0.18 to 0.78); Letter Cancellation (MD 10.60, 95% CI 2.07 to 19.13); Sentence Reading (MD 0.20, 95% CI -0.69 to 1.09), and the Wundt-Jastrow Area Illusion Test (MD -4.40, 95% CI -8.28 to -0.52); no statistical significance was observed for the same

2015 Cochrane

165. Wakix - pitolisant. Narcolepsy

is involved in the trigger of HCl secretion and is partly controlled by H3R, specific studies were performed with an acetylcholine esterase inhibitor, rivastigmine, which is known to increase gastric acid secretion. Pitolisant at up to 10 mg/kg p.o did not induce gastric ulcer when given alone or in combination with rivastigmine. Since rivastigmine alone did not induce gastric ulcer in the experimental conditions of this assay, a conclusion on the lack of potentiation of rivastigmine’s effect on gastric (...) with rivastigmine enhanced the ability of both compound to increase extracellular acetylcholine levels. Some interactions were found with lisuride and ropinirole (D2 agonists used in the treatment of PD), but were assessed to be caused by PK interactions. 2.3.3. Pharmacokinetics In rats dosed with [ 14 C]-pitolisant the bioavailability was only 1.5% when unchanged pitolisant was considered and nearly 100% when total [ 14 C] was considered. This can be explained by an active first- Assessment report EMA/828546

2016 European Medicines Agency - EPARs

166. Clinical practice guidelines for dementia in Australia Full Text available with Trip Pro

that the person with dementia (or their carer[s] or family) make an appointment to see a dentist to conduct an assessment and formulate a long-term treatment plan. Acetylcholinesterase inhibitors and memantine are routinely prescribed for people with mild to moderate Alzheimer disease in order to delay functional decline, and the guidelines support their use. Based on recent evidence, the guidelines also state that any one of the three acetylcholinesterase inhibitors (donepezil, galantamine or rivastigmine (...) Education Services, Department of Health and Ageing Pharmaceutical Policy Branch, Ahmed R. Post market review: Pharmaceutical Benefits Scheme anti-dementia medicines to treat Alzheimer disease. Canberra: Department of Health, 2012. (accessed Jan 2016). Birks J, Craig D. Galantamine for vascular cognitive impairment. Cochrane Database Syst Rev 2006; (1): CD004746. Birks J, McGuinness B, Craig D. Rivastigmine for vascular cognitive impairment. Cochrane Database Syst Rev 2013; (5): CD004744. Malouf R

2016 MJA Clinical Guidelines

167. Cochrane team criticises the ECDC experts' draft advice on oseltamivir use

efficacy and safety have not been established. Translated from Med Check-TIP (in Japanese) Mar. 06 ; 6 (63):3-7Page 4· MED CHECK - TIP April 2016/ Vol.2 No.4 New Products New Products (Reminyl) and rivastigmine (Rivastouch, Exelon Patch); and an NMDA receptor antagonist (NMDA antagonist), memantine (Memary) (Table). Cholinesterase inhibitors are expected to activate mental activities by increasing acetylcholine in the brain. Memantine is expected to exhibit the similar effect by inhibiting NMDA

2016 Med Check - The Informed Prescriber

168. Management of Behavioural and Psychological Symptoms of Dementia (BPSD)

of cholinesterase inhibitor therapy for management of BPSD. In this review they 8 analysed 14 clinical trails examining the efficacy of donepezil, rivastigmine and galantamine for management of BPSD. In this review only three studies showed statistically significant and clinically modest benefit. They supported cholinesterase inhibitor therapy for management of BPSD in the absence of effective and safe alternative therapy. A systematic review by Henry and colleagues 99 and a Cochrane review by Seitz et al 100

2016 Australian and New Zealand Society for Geriatric Medicine

170. Dementia

(NICE) guidelines Dementia: supporting people with dementia and their carers in health and social care [ ] and Dementia, disability and frailty in later life – mid-life approaches to delay or prevent onset [ ], the NICE Technology Appraisal Donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease [ ], the European Federation of Neurological Societies (EFNS-ENS) Guidelines on the diagnosis and management of disorders associated with dementia [ ], and the Guidelines (...) published since the last review of this topic. No major changes to recommendations have been made, but the topic has undergone minor restructuring. Previous changes Previous changes June 2015 — minor update. Based on an update in 2015 to the manufacturer's Summary of Product Characteristics (SPC), decreased appetite has been included as a common adverse effect of rivastigmine. April 2015 — minor update. Update to the text to reflect new advice from the Department of Transport on drugs and impaired

2019 NICE Clinical Knowledge Summaries

171. Drugs to avoid in 2015

of their disproportionate adverse effects and many interactions with other drugs. None of the available drugs has been shown to slow progression toward dependency, yet all carry a risk of life-threatening adverse effects and severe drug inter - actions (Prescrire Int n° 128 and Rev Prescrire n° 363, 364). It is better to focus on reorganising the patient’s daily life, keeping him or her active, and providing support and help for caring relatives. – Donepezil, galantamine and rivastigmine, three cholinesterase

2015 Prescrire

173. Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials. Full Text available with Trip Pro

patients at 119 sites; study 2: n = 858 at 158 sites; and study 3: n = 734 at 126 sites). The 24-week studies were conducted from October 2013 to January 2017; final follow-up on January 12, 2017.Idalopirdine (10, 30, or 60 mg/d) or placebo added to cholinesterase inhibitor treatment (donepezil in studies 1 and 2; donepezil, rivastigmine, or galantamine in study 3).Primary end point in all 3 studies: change in cognition total score (range, 0-70; a lower score indicates less impairment) from baseline

2018 JAMA Controlled trial quality: predicted high

175. Reviews: Effects of transdermal rivastigmine on ADAS-cog items in mild-to-moderate Alzheimer's disease. Full Text available with Trip Pro

Reviews: Effects of transdermal rivastigmine on ADAS-cog items in mild-to-moderate Alzheimer's disease. Alzheimer's disease (AD) patients treated with rivastigmine transdermal patch have shown statistically significant differences versus placebo on the AD Assessment scale-cognitive subscale (ADAS-cog). In this retrospective analysis of a double-blind, placebo- and active-controlled, 24-week clinical trial, the specific effects of rivastigmine patch on individual ADAS-cog items and cognitive (...) domains (memory, language, and praxis) were explored. The mean baseline to week 24 changes were calculated for each ADAS-cog item and domain in this exploratory, hypothesis-generating analysis. Patients on 9.5 mg/24 h rivastigmine patch, 17.4 mg/24 h rivastigmine patch, and 3 to 12 mg/d rivastigmine capsules showed improvements over placebo on the memory and praxis ADAS-cog subscales. The rivastigmine patch groups also showed improvements on the language subscale. Significant differences versus

2010 American journal of Alzheimer's disease and other dementias

176. Bioequivalence Study of Rivastigmine 1.5 mg Capsules Under Fasting Conditions

Bioequivalence Study of Rivastigmine 1.5 mg Capsules Under Fasting Conditions Bioequivalence Study of Rivastigmine 1.5 mg Capsules Under Fasting Conditions - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Bioequivalence Study of Rivastigmine 1.5 mg Capsules Under Fasting Conditions The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01146067 Recruitment Status : Completed First Posted : June 17, 2010 Last Update Posted : January 13, 2012 Sponsor: Dr. Reddy's Laboratories Limited Information provided by: Dr

2010 Clinical Trials

177. Bioequivalence Study of Rivastigmine Capsules 1.5 mg of Dr.Reddy's Under Fed Conditions

Bioequivalence Study of Rivastigmine Capsules 1.5 mg of Dr.Reddy's Under Fed Conditions Bioequivalence Study of Rivastigmine Capsules 1.5 mg of Dr.Reddy's Under Fed Conditions - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies (...) before adding more. Bioequivalence Study of Rivastigmine Capsules 1.5 mg of Dr.Reddy's Under Fed Conditions The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01146041 Recruitment Status : Completed First Posted : June 17, 2010 Last Update Posted : June 17, 2010 Sponsor: Dr. Reddy's Laboratories Limited

2010 Clinical Trials

178. Effects of Exercise and Rivastigmine on Quality of Life of Alzheimer's Disease Patients

Effects of Exercise and Rivastigmine on Quality of Life of Alzheimer's Disease Patients Effects of Exercise and Rivastigmine on Quality of Life of Alzheimer's Disease Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies (...) before adding more. Effects of Exercise and Rivastigmine on Quality of Life of Alzheimer's Disease Patients The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01183806 Recruitment Status : Completed First Posted : August 18, 2010 Last Update Posted : March 20, 2012 Sponsor: Federal University of Bahia

2010 Clinical Trials

179. Rivastigmine as a Treatment for Methamphetamine Dependence

Rivastigmine as a Treatment for Methamphetamine Dependence Rivastigmine as a Treatment for Methamphetamine Dependence - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Rivastigmine as a Treatment (...) Party): Richard De La Garza, Baylor College of Medicine Study Details Study Description Go to Brief Summary: To study the effects of treatment with rivastigmine on craving produced by experimental administration of methamphetamine. Condition or disease Intervention/treatment Phase Methamphetamine Dependence Substance Abuse Methamphetamine Abuse Other: Placebo Drug: Rivastigmine Phase 1 Detailed Description: We recently completed a double-blind placebo-controlled human laboratory study demonstrating

2010 Clinical Trials

180. Rivastigmine Study in Adolescents With Down Syndrome

Rivastigmine Study in Adolescents With Down Syndrome Rivastigmine Study in Adolescents With Down Syndrome - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Rivastigmine Study in Adolescents With Down Syndrome (...) at Kennedy Krieger, Inc. Information provided by (Responsible Party): Duke University Study Details Study Description Go to Brief Summary: The purpose of this study is to determine if short term use of rivastigmine can improve functional abilities (for example, language, memory, and executive function) in adolescents with Down syndrome. Condition or disease Intervention/treatment Phase Down Syndrome Drug: Rivastigmine Other: Liquid Placebo Phase 1 Phase 2 Detailed Description: This 24 week, double-blind

2010 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>